SKIP TO MAIN CONTENT

Research gives mesothelioma sufferers hope

A new treatment being pioneered by Sydney mesothelioma cancer researchers has created excitement in the scientific world.

2 min read

Published

Source: AAP


Skip to article content

There may be light at the end of the tunnel for mesothelioma sufferers.

The rare cancer, which results from exposure to asbestos, kills most patients but a team of Sydney oncology experts has found injecting sufferers with missing genetic information can reverse tumour growth.

"This has created considerable excitement in the scientific world," the study's principal investigator, Professor Nico van Zandwijk, said on Friday.

Researchers first identified that mesothelioma sufferers' cancerous cells were missing important nucleotides, called microRNA.

This genetic information, present in all normal cells, not only controls cell function but prevents cancer growth.

News that makes sense

Your trusted source for staying up-to-date with the world around you. Get free daily news updates and analysis, straight to your inbox.

By subscribing, you agree to SBS’s terms of service and privacy policy including receiving email updates from SBS.

Armed with this knowledge, the team began injecting patients' deficient cells with microRNA.

After four years of trials they discovered replacing the missing microRNA nucleotides stopped cancer growth and could reduce tumour size.

"This is a magnificent finding," Prof van Zandwijk from Sydney University's Concord Clinical School told AAP.

But there's a lot more work to be done before the treatment could be used to fight mesothelioma in the real world.

Prof van Zandwijk says more clinical trials are required over at least six years before the treatment could be registered.

Australia has one of the highest rates of mesothelioma in the world due to mining and the widespread use of asbestos in building materials up until the 1980s.

The cancer, which originates in the tissues lining the lung, is resistant to almost all forms of therapy.

Only 40 per cent of patients respond to standard chemotherapy which adds just months to their lives.

The results of the trial have been published in the latest issue of Lancet Oncology.


Get SBS News straight to your inbox

Sign up now for daily news from Australia and around the world. You can also subscribe to Insight's weekly newsletter for in-depth features and first-person stories.

By subscribing, you agree to SBS’s terms of service and privacy policy including receiving email updates from SBS.

Follow SBS News

Download our apps

Listen to our podcasts

Get the latest with our News podcasts on your favourite podcast apps.

Watch on SBS

SBS World News

Take a global view with Australia's most comprehensive world news service

Stream now

Watch the latest news videos from Australia and across the world